Pasithea Therapeutics (KTTA)

Executive Summary

Pasithea Therapeutics is a clinical-stage biotechnology company advancing novel therapeutics for central nervous system (CNS) disorders and RASopathies. The company's pipeline includes programs targeting Neurofibromatosis type 1 (NF1), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and schizophrenia. Leveraging its expertise in antibody, biologic, and small molecule modalities, Pasithea aims to address significant unmet needs in neurological conditions. With a market capitalization of approximately $17.5 million, the company is in early development stages and has yet to generate revenue from product sales. Key milestones include preclinical and clinical data readouts, which could serve as critical value drivers. As a publicly traded entity (KTTA), Pasithea's near-term prospects hinge on successful advancement of its lead candidates and ability to secure additional funding or partnerships.

Upcoming Catalysts (preview)

• Q4 2025Initiation of Phase 1 trial for lead CNS candidate40% success
• Q2 2025Preclinical data release for NF1 program50% success
• H2 2025Partnership or grant announcement to support ALS program30% success